These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12698199)

  • 1. Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells.
    Gritzapis AD; Mamalaki A; Kretsovali A; Papamatheakis J; Belimezi M; Perez SA; Baxevanis CN; Papamichail M
    Br J Cancer; 2003 Apr; 88(8):1292-300. PubMed ID: 12698199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc(epsilon) RI.
    Mamalaki A; Gritzapis AD; Kretsovali A; Belimezi M; Papamatheakis J; Perez SA; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2003 Aug; 52(8):513-22. PubMed ID: 12715240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells.
    Moritz D; Wels W; Mattern J; Groner B
    Proc Natl Acad Sci U S A; 1994 May; 91(10):4318-22. PubMed ID: 7910405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo.
    Gritzapis AD; Perez SA; Baxevanis CN; Papamichail M
    Br J Cancer; 2005 Jan; 92(1):72-9. PubMed ID: 15583693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity.
    Moritz D; Groner B
    Gene Ther; 1995 Oct; 2(8):539-46. PubMed ID: 8593604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
    Gritzapis AD; Sotiriadou NN; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2004 Nov; 53(11):1027-40. PubMed ID: 15164233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytolytic and cytotoxic activity of a human natural killer cell line genetically modified to specifically recognize HER-2/neu overexpressing tumor cells.
    Demirtzoglou FJ; Papadopoulos S; Zografos G
    Immunopharmacol Immunotoxicol; 2006; 28(4):571-90. PubMed ID: 17190735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma.
    Haynes NM; Snook MB; Trapani JA; Cerruti L; Jane SM; Smyth MJ; Darcy PK
    J Immunol; 2001 Jan; 166(1):182-7. PubMed ID: 11123291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes.
    Altenschmidt U; Kahl R; Moritz D; Schnierle BS; Gerstmayer B; Wels W; Groner B
    Clin Cancer Res; 1996 Jun; 2(6):1001-8. PubMed ID: 9816261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
    Ko HJ; Kim YJ; Kim YS; Chang WS; Ko SY; Chang SY; Sakaguchi S; Kang CY
    Cancer Res; 2007 Aug; 67(15):7477-86. PubMed ID: 17671218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biotechnological and gene therapeutic strategies in cancer treatment.
    Wels W; Moritz D; Schmidt M; Jeschke M; Hynes NE; Groner B
    Gene; 1995 Jun; 159(1):73-80. PubMed ID: 7607575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells.
    Mezzanzanica D; Canevari S; Mazzoni A; Figini M; Colnaghi MI; Waks T; Schindler DG; Eshhar Z
    Cancer Gene Ther; 1998; 5(6):401-7. PubMed ID: 9917095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
    Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
    Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells.
    Kaplan BL; Norell H; Callender GG; Ohlum T; Kiessling R; Nishimura MI
    Cancer Immunol Immunother; 2006 Jun; 55(6):653-62. PubMed ID: 16151808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
    Baxevanis CN; Gritzapis AD; Tsitsilonis OE; Katsoulas HL; Papamichail M
    Int J Cancer; 2002 Apr; 98(6):864-72. PubMed ID: 11948464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redirecting effector T cells through their IL-2 receptors.
    Lustgarten J; Marks J; Sherman LA
    J Immunol; 1999 Jan; 162(1):359-65. PubMed ID: 9886407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
    Sun M; Shi H; Liu C; Liu J; Liu X; Sun Y
    Breast Cancer Res; 2014 Jun; 16(3):R61. PubMed ID: 24919843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model.
    Yoon SH; Lee JM; Cho HI; Kim EK; Kim HS; Park MY; Kim TG
    Cancer Gene Ther; 2009 Jun; 16(6):489-97. PubMed ID: 19096447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour.
    Linehan DC; Peoples GE; Hess DT; Summerhayes IC; Parikh AS; Goedegebuure PS; Eberlein TJ
    Surg Oncol; 1995 Feb; 4(1):41-9. PubMed ID: 7780612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.
    Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
    Blood; 2002 Nov; 100(9):3155-63. PubMed ID: 12384413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.